AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04281797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal microbiome new generation sequencing
Description: Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
Study NCT00800072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOWOX
Description: one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
Study NCT00606515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel
Description: Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
Study NCT00606515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
Study NCT02739087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI guided cardiac catheterization
Description: Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
Study NCT02739087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Study NCT06563024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FET PET/CT
Description: The enrolled patients receive the 18F-FET PET/CT.
Study NCT04350359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variable-dose TTNS Protocol 5 x week
Description: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
Study NCT04350359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-dose TTNS Protocol
Description: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.
Study NCT04350359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variable-dose TTNS Protocol 2 x week
Description: At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
Study NCT01628835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dietary glycemic index diet
Description: Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
Study NCT01628835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National recommendation diet
Description: Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
Study NCT01124175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 100 mg Tablets
Study NCT01124175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozaar®
Description: 100 mg Tablets
Study NCT01826058 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Study NCT03916263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Traditional care including diet, exercise and metformin
Study NCT03916263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: One-On-One Dietary Instruction
Description: Participant receives one-on-one dietary counseling from study personnel
Study NCT03916263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video Dietary Instruction
Description: Participant receives video dietary instruction
Study NCT02163837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximine
Study NCT02269995 — intervention group
Intervention type: DEVICE
Intervention: E7040
Description: E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
Study NCT01148030 — intervention group
Intervention type: DRUG
Intervention: 3M Skin and Nasal Antiseptic
Description: Intra-nasal dosing
Study NCT02173834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan
Study NCT01753375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 given as 50000 IU orally on weekly basis
Study NCT01753375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be given orally on weekly basis
Study NCT02356978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm1 homemade phototherapy treatment
Description: session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights.
Study NCT02356978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRAP
Study NCT01163461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech therapy
Description: individuals will receive 60 hours of behavioral speech therapy
Study NCT03772522 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: dk Leadership
Description: Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
Study NCT03772522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dk Leadership
Description: Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
Study NCT05278507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrowga+rd Blue Advance Protection PICC Placement
Description: The PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
Study NCT05278507 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator PICC placement
Description: The sham comparator PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
Study NCT02956460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: contact lens
Study NCT02956460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: contact lens
Study NCT03734718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP
Description: Infusion of Glucose-dependent insulinotropic peptide
Study NCT03734718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIP
Description: Infusion of Glucose-dependent insulinotropic peptide
Study NCT05299450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
Study NCT04656080 — intervention group
Intervention type: BEHAVIORAL
Intervention: CPET exercise testing
Description: * The cardiopulmonary exercise testing (CPET) is done.~* EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET.
Study NCT02378935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food
Study NCT02378935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily with food
Study NCT02378935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT02951273 — intervention group
Intervention type: OTHER
Intervention: Study of cerebral blood flow
Description: Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml.
Study NCT01931865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
Study NCT00835991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin 5 mg/500 mg Tablets
Description: 1 x 5 mg/500 mg, single-dose fed
Study NCT00835991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucovance® 5 mg/500 mg Tablets
Description: 1 x 5 mg/500 mg, single-dose fed
Study NCT03890796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Scheduling
Description: AS is strategy for behavioral activation that has also been used with success in people with dementia, after the training of their caregivers. A certified occupational therapist will train up the caregivers of dementia in conducting AS activities for participants in experimental group
Study NCT03890796 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Educational
Description: A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
Study NCT00047411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Resuscitation
Description: Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
Study NCT00047411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic External Defibrillation
Description: Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 1mg
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 2.5mg
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 5mg
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 10mg
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 25mg
Study NCT03890796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational
Description: A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
Study NCT02914990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-15086
Description: BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 1mg)
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 2.5mg)
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 5mg)
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 10mg)
Study NCT01879020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (TA-8995 25mg)
Study NCT01936038 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Description: CPAP
Study NCT01936038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP
Study NCT01936038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Airway Toning for Improve the Compliance of CPAP
Description: Upper Airway Toning for Improve the Compliance of CPAP
Study NCT00904254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EP 1645/Solution For Injection, 99mTC
Description: (Fab-fragment of Anti-human CD4,technetium-99m)
Study NCT03270722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIP topography
Description: During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
Study NCT02437747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP + Aloe
Description: Scaling and root planing along with aloe vera application was done
Study NCT02437747 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SRP
Description: Scaling and root planing was done
Study NCT04503603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
Study NCT04503603 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.
Study NCT02955641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Disodium Phosphate 0.1%
Description: four drops a day for four days after LPI treatment
Study NCT02955641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.1%
Description: four drops a day for four days after LPI treatment
Study NCT02955641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethylcellulose 0.19%
Description: four drops a day for four days after LPI treatment
Study NCT00159406 — intervention group
Intervention type: OTHER
Intervention: Registry and Database
Description: Data Collection
Study NCT00984568 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab intravenous infusion at a dose of 5 mg/kg.
Study NCT00984568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab intravenous infusion at a dose of 5 mg/kg.
Study NCT00984568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
Study NCT00984568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
Study NCT00984568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-aminosalicylic acid
Description: 5-ASA administered orally at a dose of 2 g/day.
Study NCT00984568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
Study NCT00984568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
Study NCT02964507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: GSK525762 will be administered.
Study NCT02964507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT02964507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered.
Study NCT02964507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant will be administered.
Study NCT02783469 — intervention group
Intervention type: GENETIC
Intervention: Identification of genetic causes of diabetic neuropathic pain
Study NCT03270722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLIP topography
Description: During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
Study NCT01987674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-meal protein drink
Study NCT03270722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy
Description: A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
Study NCT03270722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Endoscopy
Description: A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
Study NCT02917590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task obstacle crossing training
Description: Obstacle crossing simultaneously a color word stroop task training
Study NCT02917590 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Single-task obstacle crossing training
Description: Obstacle crossing training
Study NCT03021902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV amino acids
Description: IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.
Study NCT03021902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-bed cycle ergometry exercise
Description: In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.~Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay.
Study NCT02774590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.